M
Maureen E. Trudeau
Researcher at Sunnybrook Health Sciences Centre
Publications - 259
Citations - 14303
Maureen E. Trudeau is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 51, co-authored 235 publications receiving 12424 citations. Previous affiliations of Maureen E. Trudeau include York University & Women's College Hospital.
Papers
More filters
Journal ArticleDOI
The Perceptions and Expectations of Older Women in the Establishment of the Senior Women's Breast Cancer Clinic (SWBCC): a Needs Assessment Study.
Michael C. Tjong,Ines B Menjak,Maureen E. Trudeau,Rajin Mehta,Frances C. Wright,Angela Leahey,Janet Ellis,Damian Gallagher,Leslie Gibson,Bonnie Bristow,Katie Rice,Ewa Szumacher,Ewa Szumacher +12 more
TL;DR: There were important gaps in the cancer care of older women with breast cancer that could be detected earlier and better addressed in the new multidisciplinary SWBCC.
Journal ArticleDOI
Prospective evaluation of the impact of the 21-gene recurrence score® assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada
Sofia Torres,Maureen E. Trudeau,Sonal Gandhi,Ellen Warner,S. Verma,Kathleen I. Pritchard,Teresa M. Petrella,Elzbieta Slodkowska,M. Hew-Shue,C. Chao,Andrea Eisen +10 more
Journal ArticleDOI
Interpreting the febrile neutropenia rates from randomized controlled trials for consideration of primary prophylaxis in the real world: A systematic review and meta-analysis.
TL;DR: A systematic literature search was conducted using MEDLINE, EMBASE, and CENTRAL databases for full-length articles reporting FN rates for breast cancer-related chemotherapies between Jan/96 and Feb/14 to model the odds ratio (OR) of FN.
Journal ArticleDOI
A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer.
Tiffany A. Traina,Joyce O'Shaughnessy,Catherine M. Kelly,Lee S. Schwartzberg,Ayca Gucalp,Amy C. Peterson,Iulia Cristina Tudor,Martha Elizabeth Blaney,Joyce Steinberg,Maureen E. Trudeau,Clifford A. Hudis,Peter Schmid +11 more
TL;DR: Women with advanced AR+ TNBC will receive daily ENZA (160 mg) until disease progression (NCT01889238) and benefit is defined as complete or partial response (CR or PR) or stable disease (SD) ≥16 weeks (wks) as assessed by the Investigator and according to RECIST 1.1.2.
Journal ArticleDOI
A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22
Maureen E. Trudeau,Judith-Anne W. Chapman,Baoqing Guo,Mark Clemons,Rebecca Dent,Roberta A. Jong,Harriette J. Kahn,Kathleen I. Pritchard,Lei Han,Patti O'Brien,Lois E. Shepherd,Amadeo M. Parissenti +11 more
TL;DR: The combination regimens had acceptable toxicity, good clinical response, induction of changes in tumor RNA content and integrity, and the role of novel response biomarkers was explored.